Abstract 189P
Background
The randomized, 2-part, open-label, phase 3 LEAP-014 study (NCT04949256) is being conducted to evaluate the safety and efficacy of len + pembro + chemo vs pembro + chemo in patients with previously untreated metastatic ESCC. Results from the safety run-in cohort (part 1) are reported.
Methods
Eligible patients had histologically or cytologically confirmed previously untreated metastatic ESCC, measurable disease per RECIST v1.1 by investigator assessment, and ECOG PS score 0 or 1. In part 1, patients received induction with pembro 400 mg IV Q6W ×2 cycles + len 8 mg PO QD + chemo (cisplatin + 5-FU [FP cohort] Q3W ×4 cycles or paclitaxel + cisplatin [TP cohort] Q3W ×4 cycles) and consolidation with pembro 400 mg IV Q6W for ≤16 cycles + len 20 mg PO QD. Treatment continued until disease progression or unacceptable toxicity. Primary end points for part 1 were dose-limiting toxicities (DLTs), adverse events (AEs), and discontinuations due to AEs. DLTs were evaluated for 21 days after the first dose; if ≥3 DLTs occurred in the TP or FP cohort, then part 2 could be delayed to further examine safety data and consider study design changes.
Results
At data cutoff (February 2, 2023), 13 patients were treated (FP cohort, n = 7; TP cohort, n = 6). Median time from first dose to data cutoff was 16.6 months (range, 15.9-17.3) and 5.6 months (4.6-6.2) with len + pembro + FP and len + pembro + TP, respectively. Median (range) age was 64 years (43-77) and 66 years (53-71), respectively. One DLT of grade 3 acute kidney injury associated with increased creatinine level and 1 DLT of grade 3 hypokalemia occurred in the FP cohort; no DLTs were reported in the TP cohort. No patient discontinued because of a DLT and no treatment-related deaths occurred. Preliminary efficacy results will be reported.
Conclusions
Part 1 (safety run-in) of LEAP-014 showed that len + pembro + chemo had acceptable safety and tolerability in patients with previously untreated metastatic ESCC, allowing initiation of part 2. Part 2 is ongoing and is evaluating the efficacy and safety of len + pembro + chemo vs pembro + chemo as first-line therapy for patients with metastatic ESCC.
Clinical trial identification
NCT0494926.
Editorial acknowledgement
Medical writing and/or editorial assistance was provided by Obinna Ezeokoli, PhD, and Andrea Humphries, PhD, CMPP, of ApotheCom (Yardley, PA,USA). This assistance was funded by Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,Rahway, NJ, USA.
Legal entity responsible for the study
Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding
Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
S. Yamamoto: Financial Interests, Personal, Invited Speaker: Ono, Bristol Myers Squibb, MSD. C. Rojas: Financial Interests, Personal, Advisory Board: BMS, Roche, Roche, MSD, Pfizer, Sanofi; Financial Interests, Personal, Invited Speaker: BMS, MSD, AstraZeneca, Knight, Pfizer; Financial Interests, Personal, Member of Board of Directors: Bradford Hill. F. Rivera Herrero: Financial Interests, Personal and Institutional, Advisory Board: MSD, Lklly, Astellas, BMS, Roche, Amgen, Merck-Serono, Servier; Financial Interests, Personal and Institutional, Invited Speaker: MSD, Lklly, Astellas, BMS, Roche, Amgen, Merck-Serono, Servier, Novartis; Financial Interests, Personal and Institutional, Research Grant: MSD, AstraZeneca, BMS, Amgen, Merck-Serono, Servier, Novartis; Financial Interests, Personal and Institutional, Funding: MSD, AstraZeneca, BMS, Roche, Amgen, Merck-Serono, Servier, Novartis; Financial Interests, Personal and Institutional, Principal Investigator: MSD, AstraZeneca, Amgen, Servier. L. Yu: Financial Interests, Institutional, Full or part-time Employment: Merck & Co.; Financial Interests, Institutional, Stocks/Shares: Merck & Co. S. Shah: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. P. Bhagia: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck. L. Shen: Financial Interests, Personal, Other, Consulting fees: Mingji biopharmaceutical, Haichuang pharmaceutical, Herbour biomed; Financial Interests, Personal, Advisory Board: MSD, Merck, BMS, BI, Sanofi, Roche, Servier, AZ; Financial Interests, Institutional, Funding: Beijing Xiantong Biomedical Technology, Qilu Pharmaceutical, ZaiLab Pharmaceutical (Shanghai), Alphamab Oncology, Yaojie Ankang (Nanjing) Technology Co., Ltd., BeiGene, Ltd., Qiyu Biotechnology (Shanghai) Co., Ltd., BriSTAR immunotech; Financial Interests, Institutional, Local PI: Merck Healthcare KGaA, Roche; Financial Interests, Institutional, Trial Chair: Rongchang Pharmaceutical, Innovent, BeiGene, Ltd., NovaRock Biotherapeutics Limited, Qilu Pharmaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract